- +6 03 8688 1098
- operation@cytopeutics.com
- Mon - Fri: 9:00 - 17:00
MI Norlinah1 , HJ Tan1 , SP Chin3 , ZK Law1 , I Nor Azimah2 , NA Nur’Ain3 , SK Cheong3,4, SAW Fadilah1,2
1 Department of Medicine, 2 Cell Therapy Center, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, 3 Cytopeutics, Malaysia, 4 Tunku Abdul Rahman University, Malaysia.
Our results showed that patients with acute stroke who received BM-MSC infusion benefited from significant improvement in clinical disability and functional outcome as early as 6 weeks of follow-up. The benefit was sustained up to 12 months follow-up and may potentially reduce mortality from sepsis.
Figure 1: The mean of NIHSS score at baseline and after (6 weeks, 3, 6, 9 and 12 months) BM-MSC infusion. *One-way ANOVA. Scheffe’s post-hoc multiple comparison was used to test the difference between each visit (p<0.05).
Figure 2: The mean of Barthel Index score at baseline and after (6 weeks, 3, 6, 9 and 12 months) BM-MSC infusion. *One-way ANOVA Scheffe’s post-hoc multiple comparison was used to test the difference between each visit (p=0.04).
Copyright © 2022 Cytopeutics Sdn Bhd. All Rights Reserved.
Abstracts & Publications